Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives-Reference-Cited by-同舟云学术

Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives

Published:2021-01-13 Issue:3 Volume:95 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Tandon Ritesh¹^ORCID,Sharp Joshua S.²³,Zhang Fuming⁴,Pomin Vitor H.²,Ashpole Nicole M.²,Mitra Dipanwita¹,McCandless Martin G.¹,Jin Weihua⁴,Liu Hao²,Sharma Poonam¹,Linhardt Robert J.⁴

Affiliation:

1. Department of Microbiology and Immunology, University of Mississippi Medical Center, Jackson, Mississippi, USA

2. Department of BioMolecular Sciences, University of Mississippi, Oxford, Mississippi, USA

3. Department of Chemistry and Biochemistry, University of Mississippi, Oxford, Mississippi, USA

4. Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, New York, USA

Abstract

The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV-2) in Wuhan, China, in late 2019 and its subsequent spread to the rest of the world has created a pandemic situation unprecedented in modern history. While ACE2 has been identified as the viral receptor, cellular polysaccharides have also been implicated in virus entry.

Funder

HHS | NIH | National Institute of General Medical Sciences

National Aeronautics and Space Administration

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/JVI.01987-20

Reference38 articles.

1. A Novel Coronavirus from Patients with Pneumonia in China, 2019

2. A new coronavirus associated with human respiratory disease in China